aspirin has been researched along with Foramen Ovale, Patent in 42 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Foramen Ovale, Patent: A condition in which the FORAMEN OVALE in the ATRIAL SEPTUM fails to close shortly after birth. This results in abnormal communications between the two upper chambers of the heart. An isolated patent ovale foramen without other structural heart defects is usually of no hemodynamic significance.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this prospective cohort study, we randomly assigned patients with PFO who had a cryptogenic stroke, in a 1:1 ratio, to dabigatran or aspirin group." | 9.51 | Dabigatran versus aspirin for stroke prevention after cryptogenic stroke with patent foramen ovale: A prospective study. ( Cai, D; Chen, S; He, J; Huang, P; Lai, Y; Sun, H; Wu, Q; Zhou, L, 2022) |
| "NAVIGATE ESUS was a double-blinded, randomised, phase 3 trial done at 459 centres in 31 countries that assessed the efficacy and safety of rivaroxaban versus aspirin for secondary stroke prevention in patients with ESUS." | 9.27 | Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. ( Ameriso, SF; Bangdiwala, S; Berkowitz, SD; Connolly, SJ; Endres, M; Hart, RG; Kasner, SE; Lavados, P; Lindgren, A; Lutsep, H; Messé, SR; Muir, K; Mundl, H; Nedeltechev, K; Olavarria, V; Perera, K; Santo, G; Sharma, M; Shoamanesh, A; Spence, JD; Swaminathan, B; Veltkamp, R, 2018) |
| "We presented a patient suffered from stroke related to thalidomide therapy." | 8.84 | [Brief report: stroke in multiple myeloma patient treated with thalidomide]. ( Hashimoto, Y; Hirano, T; Ito, Y; Mori, A; Uchino, M; Yonemura, K, 2007) |
| "Main outcomes were stroke recurrence and major bleeding." | 6.66 | Aspirin or anticoagulation after cryptogenic stroke with patent foramen ovale: systematic review and meta-analysis of randomized controlled trials. ( Calabresi, P; Cupini, LM; Eusebi, P; Giannandrea, D; Ricci, S; Romoli, M, 2020) |
| "In this prospective cohort study, we randomly assigned patients with PFO who had a cryptogenic stroke, in a 1:1 ratio, to dabigatran or aspirin group." | 5.51 | Dabigatran versus aspirin for stroke prevention after cryptogenic stroke with patent foramen ovale: A prospective study. ( Cai, D; Chen, S; He, J; Huang, P; Lai, Y; Sun, H; Wu, Q; Zhou, L, 2022) |
| "NAVIGATE ESUS was a double-blinded, randomised, phase 3 trial done at 459 centres in 31 countries that assessed the efficacy and safety of rivaroxaban versus aspirin for secondary stroke prevention in patients with ESUS." | 5.27 | Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. ( Ameriso, SF; Bangdiwala, S; Berkowitz, SD; Connolly, SJ; Endres, M; Hart, RG; Kasner, SE; Lavados, P; Lindgren, A; Lutsep, H; Messé, SR; Muir, K; Mundl, H; Nedeltechev, K; Olavarria, V; Perera, K; Santo, G; Sharma, M; Shoamanesh, A; Spence, JD; Swaminathan, B; Veltkamp, R, 2018) |
| " I have selected 4 translations in the field of vascular neurology in which I have been involved in different respects: (1) the translation of results from men to women, taking the example of aspirin which, in primary prevention, decreases the risk of myocardial infarction in men and the risk of cerebral infarction in women, the reason for this sex difference being so far unknown; (2) the 'inverse translational research', from bedside to bench, taking the example of the disease we have identified--CADASIL--and showing how the study of one patient and his family led to the identification of a gene, Notch3, so far unknown in humans and to the discovery of its key role in the physiology of vascular smooth muscle cells; (3) the translation from individual case reports to multidisciplinary trials taking the example of hemicraniectomy in malignant cerebral infarction and emphasizing the interest in such rare and severe conditions of pooling and reporting the results of randomized clinical trials before the results of individual trials, and (4) the translation from research to practice, emphasizing not the well-known 'evidence to practice gap' but the slippery slope of 'lack of evidence to overpractice', taking the example of patent foramen ovale closure in migraine." | 4.84 | Some translations in vascular neurology. The Johann Jacob Wepfer Award 2008. ( Bousser, MG, 2008) |
| "We presented a patient suffered from stroke related to thalidomide therapy." | 4.84 | [Brief report: stroke in multiple myeloma patient treated with thalidomide]. ( Hashimoto, Y; Hirano, T; Ito, Y; Mori, A; Uchino, M; Yonemura, K, 2007) |
| "When warfarin was the mainstay of anticoagulation for the prevention of cardioembolic stroke, the paradigm was essentially "we mustn't anticoagulate anyone unless we prove that the stroke was cardioembolic." | 3.91 | Anticoagulation in patients with Embolic Stroke of Unknown Source. ( Spence, JD, 2019) |
| "A cause other than paradoxical embolism was usually apparent in patients with recurrent neurologic events." | 2.77 | Closure or medical therapy for cryptogenic stroke with patent foramen ovale. ( Adams, H; Albers, GW; Felberg, R; Furlan, AJ; Herrmann, H; Kar, S; Landzberg, M; Massaro, J; Mauri, L; Raizner, A; Reisman, M; Wechsler, L, 2012) |
| "Aspirin was administered at 100 mg/d for six months after occlusion." | 2.75 | Transcatheter closure of patent foramen ovale with the Spider patent foramen ovale occluder: a prospective, single-center trial. ( Huang, T; Huang, WH; Huang, XS; Huang, YG; Shen, JJ; Xun, ZR; Zhang, CJ, 2010) |
| "Main outcomes were stroke recurrence and major bleeding." | 2.66 | Aspirin or anticoagulation after cryptogenic stroke with patent foramen ovale: systematic review and meta-analysis of randomized controlled trials. ( Calabresi, P; Cupini, LM; Eusebi, P; Giannandrea, D; Ricci, S; Romoli, M, 2020) |
| "Cryptogenic stroke is one-fourth among cerebral infarction, but most of them could be ascribed to embolic stroke." | 2.53 | [ESUS (embolic stroke of undetermined sources)]. ( Kitagawa, K, 2016) |
| "Aspirin was given as well as percutaneous endovascular PFO closure was performed with no immediate complication." | 2.47 | Patent foramen ovale and recurrent transient neurological symptoms: a case report and review of literature. ( Anamnart, C; Poungvarin, N, 2011) |
| "Stroke is a second cause of mortality worldwide and a leading cause of acquired disability in adults." | 1.38 | [Ulcerated plaques of the aorta as a cause of ischaemic stroke]. ( Hoffman, P; Kowalski, M; Michałowska, I; Rybicka, J, 2012) |
| "Cryptogenic stroke is part of the disease of stress-induced cerebrovascular disease." | 1.33 | A new theory of cryptogenic stroke and its relationship to patent foramen ovale; or, the puzzle of the missing extra risk. ( Eggers, AE, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (28.57) | 29.6817 |
| 2010's | 24 (57.14) | 24.3611 |
| 2020's | 6 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, S | 1 |
| Cai, D | 1 |
| Lai, Y | 1 |
| He, J | 1 |
| Wu, Q | 1 |
| Huang, P | 1 |
| Zhou, L | 1 |
| Sun, H | 1 |
| Sagris, D | 1 |
| Georgiopoulos, G | 1 |
| Perlepe, K | 1 |
| Pateras, K | 1 |
| Korompoki, E | 1 |
| Makaritsis, K | 1 |
| Vemmos, K | 1 |
| Milionis, H | 1 |
| Ntaios, G | 1 |
| Han, Y | 1 |
| Zhang, X | 1 |
| Zhang, F | 1 |
| Kasner, SE | 3 |
| Randall, B | 1 |
| Andersen, G | 1 |
| Iversen, HK | 1 |
| Roine, RO | 1 |
| Sjostrand, C | 1 |
| Rhodes, JF | 1 |
| Søndergaard, L | 1 |
| Romoli, M | 1 |
| Giannandrea, D | 1 |
| Eusebi, P | 1 |
| Cupini, LM | 1 |
| Ricci, S | 2 |
| Calabresi, P | 1 |
| Messé, SR | 2 |
| Gronseth, GS | 1 |
| Kent, DM | 1 |
| Kizer, JR | 1 |
| Homma, S | 1 |
| Rosterman, L | 1 |
| Carroll, JD | 1 |
| Ishida, K | 1 |
| Sangha, N | 1 |
| Diener, HC | 1 |
| Chutinet, A | 1 |
| Easton, JD | 1 |
| Granger, CB | 1 |
| Kleine, E | 1 |
| Marquardt, L | 1 |
| Meyerhoff, J | 1 |
| Zini, A | 1 |
| Sacco, RL | 1 |
| Swaminathan, B | 1 |
| Lavados, P | 1 |
| Sharma, M | 1 |
| Muir, K | 1 |
| Veltkamp, R | 1 |
| Ameriso, SF | 1 |
| Endres, M | 1 |
| Lutsep, H | 1 |
| Spence, JD | 2 |
| Nedeltechev, K | 1 |
| Perera, K | 1 |
| Santo, G | 1 |
| Olavarria, V | 1 |
| Lindgren, A | 1 |
| Bangdiwala, S | 1 |
| Shoamanesh, A | 1 |
| Berkowitz, SD | 1 |
| Mundl, H | 1 |
| Connolly, SJ | 1 |
| Hart, RG | 1 |
| Meier, B | 2 |
| Melis, M | 1 |
| Toni, D | 1 |
| Tomizawa, Y | 1 |
| Tanaka, R | 1 |
| Sekiguchi, K | 1 |
| Oji, Y | 1 |
| Tanaka, Y | 1 |
| Yamashiro, K | 1 |
| Hattori, N | 1 |
| Furlan, AJ | 2 |
| Anglim, B | 1 |
| Maher, N | 1 |
| Cunningham, O | 1 |
| Mulcahy, D | 1 |
| Harbison, J | 1 |
| O'Connell, M | 1 |
| Polzin, A | 1 |
| Dannenberg, L | 1 |
| Sophia Popp, V | 1 |
| Kelm, M | 1 |
| Zeus, T | 1 |
| Kitagawa, K | 1 |
| Savino, K | 1 |
| Maiello, M | 1 |
| Pelliccia, F | 1 |
| Ambrosio, G | 1 |
| Palmiero, P | 1 |
| Stern, S | 1 |
| Cohen, MJ | 1 |
| Gilon, D | 1 |
| Leshno, M | 1 |
| Brezis, M | 1 |
| Hudsmith, L | 1 |
| Thorne, S | 1 |
| Clift, P | 1 |
| Krizanic, F | 1 |
| Sievert, H | 1 |
| Pfeiffer, D | 1 |
| Konorza, T | 1 |
| Ferrari, M | 1 |
| Figulla, HR | 1 |
| Bousser, MG | 1 |
| Sarens, T | 1 |
| Herroelen, L | 1 |
| Van Deyk, K | 1 |
| Budts, W | 1 |
| Scacciatella, P | 1 |
| Butera, G | 1 |
| Amato, G | 1 |
| Tomassini, F | 1 |
| Giorgi, M | 1 |
| Marra, S | 1 |
| Zhang, CJ | 1 |
| Huang, YG | 1 |
| Huang, XS | 1 |
| Huang, T | 1 |
| Huang, WH | 1 |
| Shen, JJ | 1 |
| Xun, ZR | 1 |
| Fischer, D | 2 |
| Haentjes, J | 1 |
| Klein, G | 1 |
| Schieffer, B | 2 |
| Drexler, H | 2 |
| Meyer, GP | 2 |
| Schaefer, A | 2 |
| Bhindi, R | 1 |
| Ormerod, OJ | 1 |
| Anamnart, C | 1 |
| Poungvarin, N | 1 |
| Mono, ML | 2 |
| Geister, L | 1 |
| Galimanis, A | 1 |
| Jung, S | 1 |
| Praz, F | 1 |
| Arnold, M | 1 |
| Fischer, U | 1 |
| Wolff, S | 1 |
| Findling, O | 1 |
| Windecker, S | 1 |
| Wahl, A | 1 |
| Mattle, HP | 1 |
| Nedeltchev, K | 2 |
| Kalinczuk, L | 1 |
| Lubiszewska, B | 1 |
| Demkow, M | 1 |
| Arauz, A | 1 |
| Murillo, L | 1 |
| Márquez, JM | 1 |
| Tamayo, A | 1 |
| Cantú, C | 1 |
| Roldan, FJ | 1 |
| Vargas-Barrón, J | 1 |
| Barinagarrementeria, F | 1 |
| Ramponi, F | 1 |
| Wilson, MK | 1 |
| Vedelago, J | 1 |
| Bayfield, MS | 1 |
| Reisman, M | 1 |
| Massaro, J | 1 |
| Mauri, L | 1 |
| Adams, H | 1 |
| Albers, GW | 1 |
| Felberg, R | 1 |
| Herrmann, H | 1 |
| Kar, S | 1 |
| Landzberg, M | 1 |
| Raizner, A | 1 |
| Wechsler, L | 1 |
| Rybicka, J | 1 |
| Kowalski, M | 1 |
| Michałowska, I | 1 |
| Hoffman, P | 1 |
| Giger, JN | 1 |
| Brannon, CB | 1 |
| Eggers, AE | 1 |
| Müller, M | 1 |
| Paulsen, J | 1 |
| Hoerauf, H | 1 |
| Ito, Y | 2 |
| Mori, A | 2 |
| Yonemura, K | 2 |
| Hashimoto, Y | 2 |
| Hirano, T | 2 |
| Uchino, M | 2 |
| Vij, M | 1 |
| Mowbray, D | 1 |
| Ponnuthurai, FA | 1 |
| van Gaal, WJ | 1 |
| Burchell, A | 1 |
| Mitchell, A | 1 |
| Wilson, N | 1 |
| Ormerod, O | 1 |
| Fuchs, M | 1 |
| Jategaonkar, S | 1 |
| Hornig, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-blind, Evaluation in Secondary Stroke Prevention Comparing the EfficaCy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate (110 mg or 150 mg, Oral b.i.d.) Versus Acetylsalicylic Acid (100 mg Oral q.d.) in Patients With Embol[NCT02239120] | Phase 3 | 5,390 participants (Actual) | Interventional | 2014-11-27 | Completed | ||
| A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex® Septal Closure System Versus Best Medical Therapy in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism [NCT00201461] | Phase 2/Phase 3 | 900 participants (Anticipated) | Interventional | 2003-06-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Adjudicated composite of non-fatal stroke, non-fatal myocardial infarction (MI), or cardiovascular death is a key secondary endpoint. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, up to 43 months
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 4.80 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 5.40 |
Adjudicated fatal bleeding was defined as a bleeding event which the Independent Event Adjudication Committee (IAC) determined as the primary cause of death or contributed directly to death. The annualised event rate represents the average number of events per patient during a 1-year period. Because there were 0 events in one treatment group, the hazard ratio is unable to be calculated. (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 0.00 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 0.05 |
"Adjudicated intracranial haemorrhage comprised the subtypes of intracerebral bleeds, intraventricular bleeds, subdural bleeds, epidural bleeds, and subarachnoid bleeds. Microbleeds did not qualify as intracranial haemorrhage, except when they were symptomatic.~The annualised event rate represents the average number of events per patient during a 1-year period." (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 0.67 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 0.63 |
Adjudicated ischaemic stroke is a key secondary endpoint. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, up to 43 months
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 3.97 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 4.71 |
"Major bleeds were to be classified as life-threatening if they met one or more of the following criteria: fatal bleed, symptomatic intracranial bleed, reduction in haemoglobin of at least 5 grams/ deciliter (g/dL), transfusion of at least 4 units of packed red blood cells (equivalent to 9 units in Japan), associated with hypotension requiring the use of intravenous inotropic agents, or necessitated surgical intervention.~The annualised event rate represents the average number of events per patient during a 1-year period." (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 0.76 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 0.91 |
Adjudicated recurrent stroke (ischemic, hemorrhagic, or unspecified) is presented. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, approximately 43 months.
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 4.09 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 4.80 |
All-cause death is presented. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, up to 43 months
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 1.24 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 1.28 |
"This was the sum of all major and minor bleeds (Minor bleeds were clinical bleeds that did not fulfil the criteria for major bleeds), regardless of severity.~The annualised event rate represents the average number of events per patient during a 1-year period." (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 15.21 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 11.64 |
Disabling stroke (modified Rankin Scale greater than or equal to 4, as determined 3 months after recurrent stroke) is presented. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, up to 43 months
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 0.55 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 0.93 |
"First major bleed is primary safety endpoint. Major bleeds were defined according to the International Society of Thrombosis and Haemostasis (ISTH) definition as follows:~Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome and/or,~Bleeding (which should be overt) associated with a reduction in haemoglobin of at least 2 grams/ decilitre (g/dL) (1.24 millimoles Per Litre (mmol/L)), or leading to transfusion of ≥2 units of blood or packed cells (equivalent to ≥4.5 units in Japan); the haemoglobin drop should be considered to be due to and temporally related to the bleeding event and/or,~Fatal bleed. The annualised event rate represents the average number of events per patient during a 1-year period." (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 1.84 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 1.33 |
10 reviews available for aspirin and Foramen Ovale, Patent
| Article | Year |
|---|---|
Antithrombotic Treatment in Cryptogenic Stroke Patients With Patent Foramen Ovale: Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Foramen Ovale, Patent; Humans; Ischemic Attack, Transi | 2019 |
Aspirin or anticoagulation after cryptogenic stroke with patent foramen ovale: systematic review and meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Aspirin; Foramen Ovale, Patent; Humans; Ischemic Stroke; Middle Aged; Randomized Con | 2020 |
Brief history of patent foramen ovale and stroke.
Topics: Aspirin; Endovascular Procedures; Foramen Ovale, Patent; Humans; Randomized Controlled Trials as Top | 2015 |
[ESUS (embolic stroke of undetermined sources)].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Blood Coagulation Disorders; Clinical Trials as Topic; | 2016 |
Patent foramen ovale and cryptogenic stroke: from studies to clinical practice: Position paper of the Italian Chapter, International Society Cardiovascular Ultrasound.
Topics: Anticoagulants; Aspirin; Cardiac Catheterization; Echocardiography; Embolism, Paradoxical; Foramen O | 2016 |
Some translations in vascular neurology. The Johann Jacob Wepfer Award 2008.
Topics: Aspirin; Awards and Prizes; Biomedical Research; CADASIL; Cardiovascular Agents; Cardiovascular Dise | 2008 |
Economy class syndrome complicated by stroke: a rare condition due to paradoxical embolism--a case report and review of the literature.
Topics: Aircraft; Anticoagulants; Aspirin; Clopidogrel; Echocardiography; Embolism, Paradoxical; Foramen Ova | 2011 |
Patent foramen ovale and recurrent transient neurological symptoms: a case report and review of literature.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiac Surgical Procedures; Echocardiography, Tra | 2011 |
[Patent foramen ovale and stroke].
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Foramen Ovale, Patent; Humans; Platelet Aggregation In | 2012 |
[Brief report: stroke in multiple myeloma patient treated with thalidomide].
Topics: Aged; Anticoagulants; Aspirin; Embolism, Paradoxical; Foramen Ovale, Patent; Humans; Male; Multiple | 2007 |
9 trials available for aspirin and Foramen Ovale, Patent
| Article | Year |
|---|---|
Dabigatran versus aspirin for stroke prevention after cryptogenic stroke with patent foramen ovale: A prospective study.
Topics: Aspirin; Dabigatran; Foramen Ovale, Patent; Humans; Ischemic Stroke; Prospective Studies; Recurrence | 2022 |
Comparison of Antiplatelet Therapies for Prevention of Patent Foramen Ovale-Associated Stroke.
Topics: Adolescent; Adult; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Foramen Ov | 2020 |
Practice advisory update summary: Patent foramen ovale and secondary stroke prevention: Report of the Guideline Subcommittee of the American Academy of Neurology.
Topics: Adult; Aspirin; Atrial Fibrillation; Foramen Ovale, Patent; Humans; Platelet Aggregation Inhibitors; | 2020 |
Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS.
Topics: Adolescent; Adult; Anticoagulants; Aspirin; Dabigatran; Double-Blind Method; Embolic Stroke; Embolis | 2021 |
Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.
Topics: Aged; Aspirin; Cohort Studies; Double-Blind Method; Factor Xa Inhibitors; Female; Foramen Ovale, Pat | 2018 |
Clinical evaluation of a novel occluder device (Occlutech) for percutaneous transcatheter closure of patent foramen ovale (PFO).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alloys; Aspirin; Balloon Occlusion; Cardiac Catheterizat | 2008 |
Patent foramen ovale closure and migraine: are we following the wrong pathway?
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiac Catheterization; Cardiac Surgical P | 2009 |
Transcatheter closure of patent foramen ovale with the Spider patent foramen ovale occluder: a prospective, single-center trial.
Topics: Adolescent; Adult; Aged; Aspirin; Cardiac Catheterization; Echocardiography; Female; Foramen Ovale, | 2010 |
Closure or medical therapy for cryptogenic stroke with patent foramen ovale.
Topics: Adolescent; Adult; Anticoagulants; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Therapy, Co | 2012 |
23 other studies available for aspirin and Foramen Ovale, Patent
| Article | Year |
|---|---|
Patent foramen ovale closure by using transesophageal echocardiography for cryptogenic stroke: single center experience in 132 consecutive patients.
Topics: Adolescent; Adult; Aged; Aspirin; Cardiac Catheterization; Cardiac Surgical Procedures; Child; Contr | 2020 |
Optimal stroke prevention in patients with patent foramen ovale.
Topics: Aspirin; Foramen Ovale, Patent; Humans; Rivaroxaban; Secondary Prevention; Stroke | 2018 |
Anticoagulation in patients with Embolic Stroke of Unknown Source.
Topics: Anticoagulants; Aspirin; Embolism, Paradoxical; Foramen Ovale, Patent; Humans; Monitoring, Physiolog | 2019 |
Optimal stroke prevention in patients with PFO.
Topics: Aspirin; Foramen Ovale, Patent; Humans; Recurrence; Rivaroxaban; Stroke | 2019 |
Cerebral infarction in a case of Parry-Romberg syndrome.
Topics: Adult; Aspirin; Atorvastatin; Cerebral Infarction; Diffusion Magnetic Resonance Imaging; Facial Hemi | 2014 |
A rare case of cryptogenic stroke with an incidental finding of patent foramen ovale.
Topics: Adult; Aspirin; Brain Infarction; Female; Foramen Ovale, Patent; Humans; Incidental Findings; Magnet | 2015 |
Antiplatelet effects of clopidogrel and aspirin after interventional patent foramen ovale/ atrium septum defect closure.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cardiac Surgical Procedures; Clopidogrel; Comorbidity; Female | 2016 |
Cryptogenic stroke in a patient with a PFO: a decision analysis.
Topics: Anticoagulants; Aspirin; Cardiac Catheterization; Decision Trees; Foramen Ovale, Patent; Humans; Int | 2008 |
Spontaneous left atrial thrombus during patent foramen ovale closure.
Topics: Anticoagulants; Aspirin; Atrial Septum; Balloon Occlusion; Drug Therapy, Combination; Echocardiograp | 2008 |
Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism: procedural and follow-up results after implantation of the Amplatzer®-occluder device.
Topics: Aspirin; Cardiac Catheterization; Clopidogrel; Echocardiography, Transesophageal; Embolism, Paradoxi | 2011 |
Letter by Bhindi and Ormerod regarding article, "Lack of association between migraine headache and patent foramen ovale: results of a case-control study".
Topics: Aspirin; Case-Control Studies; Foramen Ovale, Patent; Humans; Migraine Disorders | 2010 |
Patent foramen ovale may be causal for the first stroke but unrelated to subsequent ischemic events.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Clopidogrel; Female; Follow-Up Studies; Foramen Ovale, Patent; | 2011 |
Normal chest radiograph and ground glass opacities on a thoracic computed tomographic scan in a patient with diffuse alveolar haemorrhage due to dual antiplatelet therapy prescribed after patent foramen ovale percutaneous device closure.
Topics: Adult; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Foramen Ovale, Patent; Hemoptysis; H | 2011 |
Long-term risk of recurrent stroke in young cryptogenic stroke patients with and without patent foramen ovale.
Topics: Adolescent; Adult; Aspirin; Female; Fibrinolytic Agents; Foramen Ovale, Patent; Humans; Male; Middle | 2012 |
Catastrophic pulmonary and paradoxical embolism.
Topics: Angiography; Aspirin; Cardiac Surgical Procedures; Critical Illness; Echocardiography, Transesophage | 2011 |
[Ulcerated plaques of the aorta as a cause of ischaemic stroke].
Topics: Acenocoumarol; Aspirin; Echocardiography; Foramen Ovale, Patent; Humans; Hydroxymethylglutaryl-CoA R | 2012 |
African-Americans and strokes: minutes and hours make the difference.
Topics: Aspirin; Black or African American; Female; Fibrinolytic Agents; Foramen Ovale, Patent; Health Statu | 2011 |
A new theory of cryptogenic stroke and its relationship to patent foramen ovale; or, the puzzle of the missing extra risk.
Topics: Adult; Aged; Aspirin; Databases, Factual; Foramen Ovale, Patent; Humans; Middle Aged; Recurrence; Ri | 2006 |
[Subtle, temporary, homonymous visual field defect--fatal causes?].
Topics: Adult; Anticoagulants; Aspirin; Cerebral Infarction; Fibrinolytic Agents; Foramen Ovale, Patent; Hem | 2007 |
[Late-onset hemorrhagic infarction in patients with patent foramen ovale: reports of two cases].
Topics: Acute-Phase Reaction; Aged; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Foramen Ovale, Patent | 2007 |
Pregnancy outcome in patients with patent foramen ovale and cerebral embolism.
Topics: Adult; Anticoagulants; Aspirin; Embolism, Paradoxical; Female; Foramen Ovale, Patent; Heparin, Low-M | 2008 |
Single centre experience with GORE-HELEX septal occluder for closure of PFO.
Topics: Adult; Aspirin; Cardiac Catheterization; Echocardiography; Female; Fibrinolytic Agents; Follow-Up St | 2009 |
Transcatheter closure of patent foramen ovale in patients with paradoxical embolism. Procedural and follow-up results after implantation of the Starflex occluder device with conjunctive intensified anticoagulation regimen.
Topics: Adult; Anticoagulants; Aspirin; Cardiac Catheterization; Embolism, Paradoxical; Female; Foramen Oval | 2008 |